Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV

March 14, 2018 8:10 AM

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found